Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1988-10-11
|
pubmed:abstractText |
This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris. The patients (n = 29) were evaluated during a 26-week single-blind dose titration phase followed by a 6-week double-blind placebo-randomized withdrawal phase. No patient withdrawals resulted from adverse events directly related to amlodipine. A comparison of the antianginal effects of amlodipine in the single-blind phase with the placebo phase showed a reduction in anginal episodes (p less than 0.001) and a decrease in sublingual nitroglycerin usage (p less than 0.01) that persisted in the treated double-blind group (n = 12). The place-bo double-blind group (n = 10) had a reduction in anginal episodes, but no significant change in sublingual nitroglycerin usage. The antiischemic effects of amlodipine were evident; there was an increase in exercise tolerance and a reduction of ST-segment depression, as seen in the 24-hour after-dose (range 23 to 30 hours) exercise tread-mill test. During single-blind therapy, total exercise time (p less than 0.001) and time to 1 mm ST depression (p less than 0.001) displayed an overall improvement. During the double-blind phase, the treated group demonstrated an improvement in total exercise time (p = 0.01) while the placebo group had no significant change. The total amount of ST depression also differed between treated and placebo groups (1.2 +/- 0.12 vs 1.8 +/- 0.17 mm, respectively, p less than 0.01). These results lend support to the clinical safety of this medication used as once-a-day therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
518-22
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2970788-Aged,
pubmed-meshheading:2970788-Amlodipine,
pubmed-meshheading:2970788-Angina Pectoris,
pubmed-meshheading:2970788-Blood Pressure,
pubmed-meshheading:2970788-Chronic Disease,
pubmed-meshheading:2970788-Clinical Trials as Topic,
pubmed-meshheading:2970788-Double-Blind Method,
pubmed-meshheading:2970788-Drug Administration Schedule,
pubmed-meshheading:2970788-Electrocardiography,
pubmed-meshheading:2970788-Exercise Test,
pubmed-meshheading:2970788-Heart Rate,
pubmed-meshheading:2970788-Humans,
pubmed-meshheading:2970788-Male,
pubmed-meshheading:2970788-Middle Aged,
pubmed-meshheading:2970788-Nifedipine,
pubmed-meshheading:2970788-Random Allocation
|
pubmed:year |
1988
|
pubmed:articleTitle |
Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris.
|
pubmed:affiliation |
Division of Cardiology, University of South Florida College of Medicine, Tampa 33612.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|